SUMMARY
SARS-CoV-2 superspreading occurs when transmission is highly efficient and/or an individual infects many others, contributing to rapid spread. To better quantify heterogeneity in SARS-CoV-2 transmission, particularly superspreading, we performed a systematic review of transmission events with data on secondary attack rates or contact tracing of individual index cases published before September 2021, prior to emergence of variants of concern and widespread vaccination. We reviewed 592 distinct events and 9,883 index cases from 491 papers. Meta-analysis of secondary attack rates identified substantial heterogeneity across 12 chosen event types/settings, with the highest transmission (25–35%) in co-living situations including households, nursing homes, and other congregate housing. Among index cases, 67% produced zero secondary cases and only 3% (287) infected >5 secondary cases (“superspreaders”). Index case demographic data was limited, with only 55% of individuals reporting age, sex, symptoms, real-time PCR cycle threshold values, or total contacts. With the data available, we identified a higher percentage of superspreaders among symptomatic individuals, individuals aged 49–64 years, and individuals with over 100 total contacts. Addressing gaps in reporting on transmission events and contact tracing in the literature is needed to properly explain heterogeneity in transmission and facilitate control efforts for SARS-CoV-2 and other infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the World Health Organization. The topic of the review was proposed by the senior author (ESG) and the WHO co-author (MVK) reviewed the manuscript and agreed to publish as a co-author; the funding agency had no role in study design, data collection and analysis, or decision to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All source data were openly available at the initiation of the study. Titles of published studies along with DOIs that were included in the review are provided in Appendix 3.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Shared senior authorship
Methods to clarify the purpose of each statistical test regarding study aims; Discussion to address additional limitations; additional figure and table added to the Supplemental Materials.
DATA AVAILABILITY
All the data were from publicly available databases. The complete database of extracted information from included studies is provided in Appendix 3.
